Article
Pharmacology & Pharmacy
Min Ye, Wei Huang, Rui Liu, Yingli Kong, Yang Liu, Xiaole Chen, Jianhua Xu
Summary: The study demonstrated that the combination treatment of ganetespib and lapatinib has synergistic inhibitory effects on HER2-positive breast cancer cells, enhancing antitumor activity through multiple pathways.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Chewei Anderson Chang, Jayu Jen, Shaowen Jiang, Azin Sayad, Arvind Singh Mer, Kevin R. Brown, Allison M. L. Nixon, Avantika Dhabaria, Kwan Ho Tang, David Venet, Christos Sotiriou, Jiehui Deng, Kwok-Kin Wong, Sylvia Adams, Peter Meyn, Adriana Heguy, Jane A. Skok, Aristotelis Tsirigos, Beatrix Ueberheide, Jason Moffat, Abhyudai Singh, Benjamin Haibe-Kains, Alireza Khodadadi-Jamayran, Benjamin G. Neel
Summary: Resistance to targeted therapies in HER2-positive breast cancer is often attributed to the presence of drug-tolerant persisters (DTPs). This study reveals that HER2 TKI treatment leads to the emergence of DTPs with different transcriptomes, and these DTPs are originated from pre-DTP cells that cycle stochastically. The findings provide insights into the ontogeny of DTPs and potential vulnerabilities for therapeutic targeting.
Article
Oncology
Arnaldo Marin, Abdullah Al Mamun, Hima Patel, Hiroaki Akamatsu, Dan Ye, Dhivya R. Sudhan, Lisa Eli, Katherine Marcelain, Benjamin P. Brown, Jens Meiler, Carlos L. Arteaga, Ariella B. Hanker
Summary: This study reveals the driver function of acquired HER2 mutations in resistance to HER2 tyrosine kinase inhibitors, and provides a potential treatment strategy to overcome this resistance.
Article
Oncology
Xiaolin Sang, Li Li, Chunhua Rui, Yichao Liu, Zundong Liu, Zhiwei Tao, Hailing Cheng, Pixu Liu
Summary: The study demonstrates that melatonin can enhance the sensitivity of HER2-positive breast cancer cells to lapatinib by promoting excessive endoplasmic reticulum stress-induced unfolded protein response and ROS accumulation. Additionally, melatonin also boosts the anti-tumor effect of lapatinib in HER2-positive breast cancer.
Article
Pharmacology & Pharmacy
Xiaodan Sun, Fen Tang, Qian Guo, Yiwen Liu, Yiqing He, Yan Du, Feng Gao, Guoliang Zhang, Cuixia Yang
Summary: The loss of hyaluronan synthase 2 (HAS2) may be related to the acquisition of endocrine resistance in estrogen receptor-positive (ER+) breast cancer, in which the upregulation of the membrane cytoskeletal protein EZ may play a key role. Inhibition of EZ can restore the sensitivity of endocrine-resistant cells to drug therapy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Cell Biology
Christopher E. Eyermann, John D. Haley, Evguenia M. Alexandrova
Summary: Breast cancer is a leading cause of cancer-related death in women globally, with HER2-positive subtype being a challenging part of sporadic breast cancer cases. Although Ganetespib shows promising efficacy in HER2-positive breast cancer, it also induces acquired resistance, suggesting that targeting Akt in combination with Ganetespib may be a more effective therapeutic strategy.
CELL DEATH & DISEASE
(2021)
Article
Oncology
Ana Carla Castro-Guijarro, Angel Matias Sanchez, Marina Ines Flamini, Christoph F. A. Vogel
Summary: This study aims to identify biomarkers for predicting disease progression and therapy efficacy in HER2-positive breast cancer, as well as to overcome resistance. Combining anti-HER2 therapies shows potential in inhibiting cell adhesion and migration critical for cancer metastasis. Deregulated proteins in resistant cells may serve as potential biomarkers of therapy response and resistance. These findings are promising for personalized breast cancer management to maximize the safety and efficacy of anti-HER2 therapies.
Article
Oncology
Sven Rosswag, Cristina L. Cotarelo, Klaus Pantel, Sabine Riethdorf, Jonathan P. Sleeman, Marcus Schmidt, Sonja Thaler
Summary: Acquired endocrine resistance and late recurrence in patients with ER+/HER2- breast cancer are complex and not fully understood. Circulating tumor cells (CTCs) from patients can provide insight into the mechanisms of acquired resistance and potential therapeutic approaches to combatting resistance.
Article
Biochemical Research Methods
A. K. M. Azad, Salem A. Alyami
Summary: This study developed a methodology using a fully Bayesian approach to discover novel driver biomarkers in cancer signaling transduction pathways, particularly focusing on aberrations in the TGF-beta signaling pathway. The research identified highly perturbed signaling pathways in lapatinib-resistant breast cancer cells and modeled the aberration in the TGF-beta pathway using causal Bayesian network analysis with MCMC sampling methods. The study also identified key driver genes associated with breast cancer progression/resistance within the perturbed TGF-beta signaling network structure.
BRIEFINGS IN BIOINFORMATICS
(2021)
Article
Oncology
Thanh Kieu Huynh, Chih-Hao Huang, Jhen-Yu Chen, Jin-Han Yao, Yi-Shiang Yang, Ya-Ling Wei, Hsiao-Fan Chen, Chia-Hung Chen, Chih-Yen Tu, Yuan-Man Hsu, Liang-Chih Liu, Wei-Chien Huang
Summary: The study revealed that elevation of miR-221 targeting p27(kip1) contributes to the development of acquired resistance to lapatinib in HER2-positive breast cancer, with Src inhibition suggested as a potential strategy to overcome this resistance.
Article
Oncology
Xiaoyu Chen, Ying Li, Zhiwei Zhou, Yanqiu Zhang, Luchen Chang, Xiujun Gao, Qing Li, Hao Luo, Kenneth D. Westover, Jialin Zhu, Xi Wei
Summary: This study firstly found that reversible senescence contributed to lapatinib (LAP) resistance in HER2+ breast cancer and identified ecto-5'-nucleotidase (NT5E) as a marker of reversible senescence in HER2+ breast cancer. We constructed NT5E targeted nanobubbles (NT5E-FITC-NBs) as a new molecular imaging modality which could both target reversible senescent cells and be used for ultrasound imaging. Cellular senescence-based ultrasound targeted imaging could identify reversible senescence early and evaluate LAP resistance effectively in HER2+ breast cancer.
Article
Multidisciplinary Sciences
Nindo B. Punturi, Sinem Seker, Vaishnavi Devarakonda, Aloran Mazumder, Rashi Kalra, Ching Hui Chen, Shunqiang Li, Tina Primeau, Matthew J. Ellis, Shyam M. Kavuri, Svasti Haricharan
Summary: Resistance to endocrine treatment in ER+ breast cancer patients is linked to activation of HER2 due to loss of mismatch repair, and inhibiting HER2 restores sensitivity to treatment. Loss of MutL and upregulation of HER2 are associated with sensitivity to HER inhibitors in ER+/HER2(-) patients.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Guilherme Nader-Marta, Veronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja
Summary: The sub-analysis of the ALTTO trial demonstrates that patients with small node-negative breast cancer treated with trastuzumab and concomitant chemotherapy have excellent long-term outcomes.
BRITISH JOURNAL OF CANCER
(2022)
Review
Oncology
Santiago Duro-Sanchez, Macarena Roman Alonso, Joaquin Arribas
Summary: A variety of treatments are available for HER2-positive breast cancer, but resistance to these therapies is common and associated with poor prognosis. Immunotherapeutic approaches are being explored to eradicate tumor cells and prevent relapse and progression. This review discusses the different immunotherapeutic strategies being tested and their potential benefits for HER2-positive breast cancer.
Article
Oncology
Chongkai Wang, Marwan Fakih
Summary: Dual HER2-targeted therapy has shown clinical benefits in RAS-wild type HER2-amplified colorectal cancer, but not in cases with HER2 mutations. This case report demonstrates successful HER2 targeting with trastuzumab + lapatinib in metastatic CRC with concurrent HER2 amplification and a HER2 S310F mutation. Treatment with trastuzumab-deruxtecan upon disease progression resulted in a short-lived response.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Medicine, Research & Experimental
Kai Fang, Yueping Zhan, Ruiqiu Zhu, Yuqian Wang, Chengqi Wu, Min Sun, Yanyan Qiu, Zeting Yuan, Xin Liang, Peihao Yin, Ke Xu
Summary: This study found that bufalin inhibits tumor microenvironment-mediated angiogenesis by targeting the STAT3 signaling pathway in vascular endothelial cells. This suggests that bufalin may be used as a new antiangiogenic adjuvant therapy for treating colorectal cancer.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Cell Biology
Jun Yang, Juan Wang, Yuan Liu, Yu Zhang, Wenjing Huang, Yu Zou, Yanyan Qiu, Weiyang Cai, Jing Gao, Hu Zhou, Yingli Wu, Weijun Liu, Qingqing Ding, Yanjie Zhang, Pei-hao Yin, Wenfu Tan
Summary: The study reveals that colorectal cancer cells exploit PGE2 to promote Hh activity in a non-canonical manner, leading to Gli-dependent proliferation. Mechanistically, PGE2 activates JNK, enabling Gli2 to evade degradation by phosphorylating Gli2 at Thr1546.
CELL DEATH & DISEASE
(2021)
Article
Biochemistry & Molecular Biology
Gang Wang, Yu Yang, Du Yi, Lu Yuan, Pei-Hao Yin, Xu Ke, Wang Jun-Jie, Min-Fang Tao
Summary: This study developed polymer-coated pH-responsive liposomes loaded with betulinic acid for chemotherapy of colorectal cancer, showing superior antitumor effects and immune regulation properties in vivo.
JOURNAL OF LIPOSOME RESEARCH
(2022)
Article
Biotechnology & Applied Microbiology
Zeting Yuan, Guohua Fan, Honglei Wu, Chaolian Liu, Yueping Zhan, Yanyan Qiu, Chenting Shou, Feng Gao, Jun Zhang, Peihao Yin, Ke Xu
Summary: Recent studies show that photodynamic therapy (PDT) can enhance the therapeutic effects of PD-L1 blockade in colorectal cancer (CRC) by inducing tumor cell death, stimulating immune response, and preventing tumor recurrence through upregulation of PD-L1 expression via the hypoxia-inducible factor 1a (HIF-1a) signaling pathway. This combination therapy using multifunctional nanoparticles loaded with photosensitized mTHPC (mTHPC@VeC/T-RGD NPs) shows promise in improving the response rate of anti-PD-L1 checkpoint blockade immunotherapies in CRC.
Article
Biotechnology & Applied Microbiology
Bingkun Zhao, Rong Zhou, Changle Ji, Diya Liu, Tianqi Wu, Hui Xu, Dongmei Lan, Chao Yao, Yuanzhi Xu, Lin Fang
Summary: This study revealed that hsa_circ_0047604 acted as a tumor suppressor and regulated breast cancer progression via hsa_circ_0047604-miR-548o-DACH1 axis, which might provide a therapeutic method for breast cancer.
BIOMED RESEARCH INTERNATIONAL
(2022)
Article
Cell Biology
Yunhe Yu, Lin Fang
Summary: This study identified circRPAP2 as a downregulated circular RNA in breast cancer, which is correlated with axillary lymph node metastasis and TNM stage, and can inhibit the proliferation and migration of breast cancer. CircRPAP2 exerts its function by affecting the binding of SRSF1 and PTK2, providing new insights into the pathogenesis of breast cancer.
CELL DEATH DISCOVERY
(2022)
Article
Cell Biology
Xuehui Wang, Hongming Song, Lin Fang, Tianqi Wu
Summary: In this study, it was found that circPRKCI, derived from the PRKCI gene, was highly expressed in TNBC and could promote the proliferation and migration of TNBC by regulating the WBP2 and PI3K/AKT signaling pathway, providing a new avenue for TNBC therapy.
CELL DEATH DISCOVERY
(2022)
Article
Pharmacology & Pharmacy
Zeting Yuan, Chaolian Liu, Yuji Sun, Yue Li, Honglei Wu, Shuli Ma, Jing Shang, Yueping Zhan, Peihao Yin, Feng Gao
Summary: This study designed iRGD-modified nanoparticles to co-deliver mTHPC and BU, aiming to enhance the efficacy of photodynamic therapy (PDT) in colorectal cancer (CRC). The nanoparticles passively accumulated in tumor cells, with mTHPC inducing apoptosis and death under laser irradiation, while the sustained release of BU inhibited hypoxia and angiogenesis by targeting the SRC-3/HIF-1α pathway.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2022)
Article
Cell Biology
Xuehui Wang, Wei Jian, Qifeng Luo, Lin Fang
Summary: In this study, a novel circRNA called circSEMA4B was identified, which could encode a protein called SEMA4B-211aa. Both circSEMA4B and SEMA4B-211aa were downregulated in breast cancer tissues and cell lines. Functional investigation revealed that circSEMA4B and SEMA4B-211aa could inhibit the proliferation and migration of breast cancer cells. CircSEMA4B inhibited AKT phosphorylation through the miR-330-3p/PDCD4 axis, while SEMA4B-211aa inhibited AKT phosphorylation by binding to p85.
CELL DEATH & DISEASE
(2022)
Article
Biochemistry & Molecular Biology
Haijing Wang, Jinbao Chen, Sen Li, Jiahua Yang, Donghao Tang, Wentao Wu, Kun Yu, Yijun Cao, Ke Xu, Peihao Yin, Yi Chen, Wei Li
Summary: Currently, recurrence and metastasis remain significant factors leading to poor prognosis in colorectal cancer (CRC) patients. Cancer-associated fibroblasts (CAFs) play a crucial role in promoting tumorigenesis and development. Bufalin, the main active monomer of the clinical drug cinobufacini, has exhibited anti-tumor activity in various cancers. However, limited research has investigated the effect of bufalin in inhibiting metastasis from the perspective of the tumor microenvironment. This study isolated CAFs from freshly resected CRC patient specimens and observed their effect on CRC cell invasion. The study also explored the physiological activity of CRC mediated by CAFs and the inhibitory effect of bufalin on CAF-mediated CRC invasion and metastasis through the STAT3 pathway.
Article
Oncology
Jinbao Chen, Jian Xu, Jiahua Yang, Yueping Zhan, Sen Li, Linlin Jia, Wentao Wu, Xianke Si, Die Zhang, Kun Yu, Peihao Yin, Yijun Cao, Wanli Deng, Ke Xu, Wei Li
Summary: Chemoresistance is a significant challenge for patients with colorectal cancer (CRC), and hypoxia is associated with poor prognosis and therapeutic resistance in cancer patients. Alpha-hederin has shown antitumour effects and can inhibit hypoxia-mediated drug resistance in CRC, but the underlying mechanism is still unclear. This study reveals that alpha-hederin inhibits drug resistance in hypoxic CRC cells by reducing AKT phosphorylation and Bcl2 expression, promoting apoptosis. These findings suggest that alpha-hederin may be a promising adjuvant for reversing drug resistance in CRC.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Jun Yang, Juan Wang, Yu Zhang, Wenjing Huang, Shaoqing Zhang, Peihao Yin, Wenfu Tan
Summary: In colorectal cancer, PGE2-JNK can activate the Hh signaling pathway non-canonically. This study demonstrates that c-Jun prevents Gli2 protein from degradation by protease through phosphorylation by PGE2. Suppression of c-Jun decreases Gli2 expression and ubiquitination, and restricts PGE2-induced Hh activity and colorectal cancer cell proliferation.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Xiaochong Deng, Kaiyao Hua, Amik Munankarmy, Qifeng Luo, Xuehui Wang, Lin Fang
Summary: This study found that PP1A expression is upregulated in hormone receptor-positive breast cancer and revealed the role of the LINC02754/E2F1/PP1A/YAP1 axis in this subtype of cancer, providing new insight into breast cancer progression.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
(2023)
Article
Oncology
Lan Xu, Shuli Ma, Bozhen Fan, Zeting Yuan, Peihao Yin
Summary: In this study, vitamin E succinate (VES)-grafted chitosan oligosaccharide (CSO)/arginine-glycine-aspartic acid peptide (RGD)-conjugated d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) mixed micelles (VeC/T-RGD MMs) were used to deliver bufalin (BU) to ovarian cancer cells to inhibit intraperitoneal metastasis. The BU-loaded VeC/T-RGD MMs (BU@MMs) effectively inhibited cell proliferation, induced apoptosis, and reduced the migration and invasion of ovarian cancer cells. The BU@MMs also showed better biocompatibility and biosafety for in vivo applications.
CANCER NANOTECHNOLOGY
(2023)
Article
Medicine, General & Internal
Juhang Chu, Luyao Huang, Yaru Wang, Lin Fang, Mingping Qian
Summary: This study found that miRNA-218-5p is upregulated in breast cancer and can promote cell proliferation, migration, and inhibit apoptosis. MiRNA-218-5p upregulates the expression of ErbB2 and EGFR by suppressing LRIG1 expression, thus promoting the malignant behaviors of breast cancer.
Article
Oncology
Masashi Nishimura, Yoshifumi Kimizuka, Takunori Ogawa, Motohiro Tsuchiya, Yoshiki Kato, Akira Matsukida, Shunya Igarashi, Koki Ito, Yusuke Serizawa, Tomomi Tanigaki, Yuji Fujikura, Yuka Katsurada, Sho Ogata, Akihiko Kawana
Summary: This study reports a case of IgG4-related retroperitoneal fibrosis occurring after chemotherapy. The patient showed improvement after discontinuing immunotherapy and receiving steroid treatment.
Article
Oncology
Yuta Ohishi, Yoko Nakanishi, Yukari Hirotani, Atsuko Suzuki, Tomoyuki Tanino, Haruna Nishimaki-Watanabe, Hiroko Kobayashi, Fumi Nozaki, Sumie Ohni, Xiaoyan Tang, Kentaro Hayashi, Yoshiko Nakagawa, Tetsuo Shimizu, Ichiro Tsujino, Noriaki Takahashi, Yasuhiro Gon, Shinobu Masuda
Summary: This study aimed to investigate the clinicopathological differences and therapeutic response of NSCLC patients with SDC4::ROS1 fusion to crizotinib. The study found that different ROS1 fusion partners may affect the efficacy of crizotinib and patient prognosis. In addition, higher expression levels of ROS1 and pERK1/2 in tumor cells of case 2 may be related to the therapeutic response and prognosis.
Review
Oncology
Zitong Zheng, Juanjuan Liu, Junling Ma, Runting Kang, Zhen Liu, Jiangyong Yu
Summary: Small cell lung cancer (SCLC) is a highly aggressive malignancy with limited treatment options. Over the past decade, immunotherapy has made progress in the treatment of SCLC, but current immune checkpoint inhibitors have limited benefits for patient survival. Therefore, it is important to explore new targets and develop drugs with novel mechanisms for immunotherapy in SCLC.
Article
Oncology
Kazuto Sugai, Kojiro Nakaoka, Rika Tobita, Shinji Kikuchi, Kei Inoue, Midori Enokido, Moriyuki Kiyoshima
Summary: This article presents a case of multilocular mediastinal cyst leading to the development of thymic cancer. Resection of multilocular anterior mediastinal cysts should be considered due to the challenges in preoperative diagnosis, the potential for coexisting tumors with cysts, and the risk of malignant tumor development.